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days to develop, as in this case [7,8]. An IgM antibody 
dlrected against ceftriaxone has been one of the 
processes in third-generation cephalosporin-induced 
hemolysis [3,8]. The clinical course of our case, with a 
duration of 10 days between hemolysis and initiation of 
the ceftriaxone therapy, laboratory results and develop- 
ment of renal failure, suggests that the process was IgM- 
type immune complex mediated [3]. 
In all of the reported cases with hemolytic anemia 
induced by ceftriaxone, the patients were immuno- 
compromised in some way. The majority of the cases 
were children and had hematologic disorders such as 
sickle cell anemia. Many of them had been exposed to 
ceftriaxone previously [1,4] but this patient could not 
recall any previous cephalosporin therapy. He was 
apparently immunocompetent. He was hospitalized for 
the first time in his life, he was completely healthy and 
he had no recurrent infection or diarrhea. 
In this fatal complication of ceftriaxone therapy, 
no risk factors, such as repeated exposure to ceftriaxone 
or pre-existing hemolytic anemia, were identified. 
Although the patient had received amoxycillin- 
clavulanate immediately prior to receiving ceftriaxone, 
this is unlikely to have been a contributing factor, as 
very little of the prescribed dose was taken. Therefore, 
every patient receiving ceftriaxone, including those 
with no underlying disease, should be observed care- 
my. Drug-induced hemolytic anemia should always be 
considered in the dfferential diagnosis of intravascular 
hemolysis in patients receiving ceftriaxone and possibly 
other third-generation cephalosporins. 
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Nosocomial diarrhea, defined as the onset of diarrhea 
more than 72 h after admission, is most frequently 
associated with Clostridium d@cile infection or drug 
administration. Other enteropathogenic bacteria, 
although common in community-acquired diarrhea, 
are rarely involved. Routine stool cultures are therefore 
generally not required in the investigation of patients 
with nosocomial diarrhea, and some microbiological 
laboratories have implemented a rejection policy for 
such samples [l]. We report on two patients who 
presented with nosocomial salmonellosis during chemo- 
therapy-induced neutropenia. 
Patient A was a 37-year-old woman with a 2- 
year history of disseminated breast carcinoma, admitted 
on 2 January 1997 for chemotherapy and peripheral 
blood stem cell transplantation. She was assigned to a 
double room with a private lavatory. She had no 
complaints and reported one or two formed bowel 
movements per day. There was no history of overseas 
travel and there were no cases of diarrhea in her family. 
Her physical examination was unremarkable except for 
a mastectomy scar. Laboratory data on admission were: 
hemoglobin 102 g/L, leukocytes 8300/pL, platelets 
180 OOO/pL, and C-reactive protein (CRP) 1 mg/L 
(normal range < 8 mg/L). High-dose chemotherapy 
with cyclophosphamide (1500 mg/m2 per day), carbo- 
platin (200 mg/m2 per day) and thiotepa (125 mg/mz 
per day) was administered from 3 January to 5 January. 
Supportive therapy included co-trimoxazole (480 mg/ 
day PO), fluconazole (100 mg/day PO), omeprazole 
(40 mg/day PO) and metoclopramide. Peripheral 
blood stem cell transplantation was performed on 
8 January, and neutropenia developed on the following 
day. From 7 January to 9 January, she experienced self- 
limited diarrhea. Stool cultures and ELISAs for C. 
dijicile toxin taken on 8 January and 12 January were 
negative. On 13 January she developed pyrexia, 
followed the next day by abdominal cramps, watery 
diarrhea and a rise of CRE? Gram-negative sepsis was 
suspected and ceftazidime (2 g/8 h IV) given. A set of 
blood cultures taken on 14 January was negative, as was 
an ELISA for fecal C. d@cile toxin. A stool culture grew 
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Salmonella derby, sensitive to ampicdin, ciprofloxacin, 
cefotaxime and co-trimoxazole. The patient became 
afebrile on 15 January, and stool habits reverted to 
normal on 21 January. Cefiazidime was given for 10 
days. Follow-up stool cultures were negative. 
Patient B was a 34-year-old woman with a 3- 
month history of disseminated breast carcinoma, 
admitted to the same room as patient A on 7 January 
1997. She reported one or two formed bowel move- 
ments per day and denied overseas travel and recent 
cases of diarrhea in her family. On  physical examina- 
tion there was a mastectomy scar. Laboratory data 
on admission were: hemoglobin 108 g/L, leukocytes 
2800/pL, platelets 169000/pL, and CRP 1 mg/L. 
High-dose chemotherapy and supportive therapy (for 
drugs and dosage, see patient A) were started on 9 
January, and peripheral blood stem cell transplanta- 
tion was performed on 14 January. Watery diarrhea 
developed on 16 January. The temperature was 37.2”C, 
and the abdomen was soft and tender. Laboratory 
investigations revealed neutropenia and a normal level 
of CRP. Stool cultures from 16,17 and 18 January grew 
S. derby with the same susceptibility pattern as the strain 
grown from the stool of patient A. C. d@cile-toxin was 
not detected. Ciprofloxacin (200 mg/12 h IV) was 
started. Follow-up stool cultures on 21 and 26 January 
were negative. The patient was discharged on 30 January. 
All stool examinations were performed in the 
Institute of Medical Microbiology and Hygiene of the 
University of Freiburg according to the guidelines of 
the German Society of Hygiene and Microbiology [2]. 
Briefly, samples are plated onto Endo agar, Leifion 
agar, and cefsulodin-irgasan-novobiocin (CIN) agar. 
Additionally, two enrichment media (Kauffmann broth 
and selenit broth) are inoculated and subcultivated after 
24 h on Endo agar, Rambach agar and brilliant green- 
phenol red-lactosesaccharose agar. CIN agar plates are 
incubated at 30°C for 48 h, and all other media are 
incubated at 37°C for 24 h. From January 1992 to 
December 1996, S. derby was cultured from a total of 
nine patients, amounting to approximately 0.35% of all 
Salmonella isolates. The most recent isolation of S. derby 
dated back to June 1996, and no further isolates were 
obtained through August 1998. 
We report on two patients who developed noso- 
comial diarrhea with S. derby. Both patients were 
immunosuppressed due to disseminated malignant 
disease and chemotherapy-induced neutropenia, and 
both were on treatment known to decrease the 
infectious dose for enteropathogens, i.e. antibiotics and 
acid-suppressive therapy. Of note is the fact that the 
administration of co-trimoxazole at a dosage aimed at 
prevention of Pneumocystis carinii infection was unable 
to prevent infection with a susceptible strain of S. derby. 
Although genetic fingerprinting was not performed, 
nosocomial transmission of S. derby from patient A to 
B can be assumed on the basis of time course, identity 
of susceptibility spectra and rarity of human isolates 
of S. derby in our area. Patient A may have acquired 
S. derby through hospital food or staff. However, 
salmonellosis did not occur in equally immunosup- 
pressed patients exposed to the same food and staff, and 
neither patient had consumed food from outside the 
hospital. We therefore consider hospital acquisition to 
be an unlikely event. The carrier rate for salmonellae 
in the population served by our laboratory is estimated 
at 4% [3], and overgrowth of S. derby in an asymp- 
tomatic carrier triggered by antibacterial and cytotoxic 
treatment appears to be a plausible explanation. 
S. derby is one of the most common serotypes 
isolated from humans in certain Asian countries 141 but 
is rarely isolated &om humans in Europe [5] and the 
USA [6]. In the area served by our laboratory, S. derby 
accounts for only 0.35% of all human Salmonella 
isolates. However, this species has been involved in an 
epidemic of nosocomial infection in the northeastern 
USA [7] and has previously been found to cause 
salmonellosis in patients with neoplastic disease with 
unexpected frequency [8]. 
Sporadic nosocomial diarrhea in adults is rarely 
caused by enteropathogenic bacteria other than C. 
d@cile. Previously undiagnosed enteropathogens are 
grown from less than 1% of routine stool cultures taken 
after the third day of hospitalization [9]. Some labora- 
tories have therefore implemented a ‘3-day rule’, 
rejecting stool culture requests on patients after the 
third day of hospitalization except under special circum- 
stances such as suspected nosocomial outbreaks [l] or 
immunosuppression [9]. However, exempting patients 
with any degree of immunosuppression from the ‘3-day 
rule’ would mitigate the effect of such a rule, given the 
high prevalence of disease- or drug-related immuno- 
suppression in internal medical patients. We feel that 
exemptions to the ‘3-day rule’ should be defined more 
precisely. Patients with malignancies undergoing chemo- 
therapy are particularly susceptible to infections with 
salmonellae and other enteropathogens because of im- 
paired cellular immune mechanisms, frequent antibiotic 
treatment, gastric acid suppression and mucositis. 
Salmonellosis in cancer patients is associated with 
considerable excess mortality [lo]. On the basis of our 
observations and previous reports [7,11,12], we suggest 
that routine stool cultures, in addition to testing for C. 
d@de toxin, be routinely performed in all neutropenic 
patients with nosocomial diarrhea. Furthermore, screen- 
ing for Salmonella carriage of patients awaiting high- 
dose chemotherapy may be appropriate, depending on 
the local fiequency of asymptomatic Salmonella carriage. 
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Resistance of Salmonella and Shigella in Turkey 
Clin Microbiol Infect 1999; 5: 588-590 
Enteric infections caused by Salmonella and Shigella are 
endemic in Turkey. Salmonella gastroenteritis is usually 
self-limiting and does not require antimicrobial therapy, 
except for some severely ill patients or patients who 
have underlying diseases [ 11. Ampicillin, chlor- 
amphenicol and trimethoprim-sulfamethoxazole are 
the antibiotics of choice for typhoid fever and some 
bacterial enteritis for which therapy is indicated [2,3]. 
High resistance rates in non-typhi Salmonella and 
Shigella strains against ampicain, chloramphenicol and 
trimethoprim-sulfamethoxazole have been reported 
[4--81. These long-used antimicrobials are being 
replaced by quinolones, as they have excellent activity 
against enteric pathogens, high intestinal luminal 
concentrations and good intracellular penetration. 
However, there are alarming reports of reduced 
susceptibility and even resistance of Salmonella strains to 
quinolones [9, lo]. We determined the antimicrobial 
resistance of Salmonella and Shigella strains isolated from 
seven different centers in Turkey. 
One hundred and ninety-two Salmonella and 
Shigella strains isolated between August 1994 and 
September 1995 were used in the study. Nineteen 
Salmonella typhi and 82 non-typhi Salmonella strains (49 
serogroup B, 26 serogroup D, four serogroup A, two 
serogroup C and one serogroup E) were isolated from 
blood and stool specimens. Shigella strains (53 Shigella 
sonnei, 33 Shigella jlexneri, four Shigella boydii and one 
Shigella dysenteriae) were all stool isolates. There were 
no duplicate isolates f k m  the same patient. The age of 
the patients ranged from 12 to 76 years. All of the 
Salmonella and Shigella strains were isolated from 
community-acquired infections. The bacteria from all 
centers were transported in Mueller-Hinton agar to the 
study center. The strains were checked for purity and 
biochemical characteristics and serotyped by using 
standard type-specific antisera (Difco, Detroit, MI, 
USA) [ll]. 
In vitro susceptibilities of Salmonella and Shigella 
strains against ampicillin, chloramphenicol, ofloxacin, 
ciprofloxacin and pefloxacin were determined by a 
broth microdilution method, whereas agar dilution was 
used for trimethoprim-sulfamethoxazole according 
to the instructions of the NCCLS [12]. Escherichia 
coli ATCC 25922 was used as the control strain. Mini- 
mum inhibitory concentrations (MICW) of ampicdin, 
chloramphenicol, ofloxacin, ciprofloxacin, pefloxacin 
and trimethoprim-sulfamethoxazole for Salmonella and 
Shigella strains and the resistance rates are given in 
Table 1. 
Three of 19 (16%) Salmonella typhi isolates were 
resistant to ampicillin, chloramphenicol and tri- 
methoprim-sulfamethoxazole. Ampicillin and chlor- 
amphenicol resistance among group B Salmonella strains 
was more striking than that of trimethoprim-sulfa- 
methoxazole. All Salmonella isolates were susceptible to 
the quinolones tested. 
